Navigation Links
YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain

MISSISSAUGA, ON, May 02, 2007 /PRNewswire-FirstCall/ - YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced top-line results from its randomized, placebo-controlled Phase IIb trial of AeroLEF(TM) in opioid naive patients with post-operative pain following orthopedic surgery. AeroLEF(TM) met the primary endpoint of the study, showing a statistically significant difference in SPRID4 from placebo (p=0.0194).

AeroLEF(TM) is a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain. Unlike fixed dose approaches to opioid delivery, where a significant titration period is often required to determine the suitable dose for the patient, AeroLEF(TM) is being developed as a non-invasive patient self-titrated delivery system designed to enable patients to identify and select a personalized dose for each pain episode, achieving both rapid onset and extended duration of analgesia.

The trial evaluated the SPRID4 for AeroLEF(TM) compared with placebo for the treatment of the first pain episode. SPRID4 is a summary of the combined changes in pain relief and in pain intensity that patients report over the first 4 hours following initiation of dosing. The trial also examined a number of secondary endpoints including various measurements of pain relief, pain intensity, as well as onset and duration of analgesia, that are commonly used as indicators of efficacy for acute pain products. Various safety measurements were also examined.

"These results continue to demonstrate the unique potential for AeroLEF(TM) to be further developed into a valuable product for pain management across a broad range of indications, which could include post-operative pain, medical emergency pain and breakthrough pain," said David All
'"/>




Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
5. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
6. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
10. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:7/22/2008)...s from a multi-center 293-patient European, trial...hange Symbol: CYT, MONTREAL, July 22 /PRNewswire-...obal leader in cryotherapy products to treat cardi...ously presented from three,European study centers ...,were published earlier today in the Journal of th...
(Date:7/22/2008)...s Development Plan Completed Successfully, DUBLIN...n Corporation,plc (NASDAQ: AMRN ) today announced...he U.S. Food and Drug Administration (FDA) to disc...treatment of,hypertriglyceridemia. Following these... with AMR101 in hypertriglyceridemia., Dr. Declan...
(Date:7/22/2008)...ntus(R) and Apidra(R) Resulted in Significant, Red...hatever the Algorithm .../ -- Results from the "Adjust to,Target in Type 2 ...ohydrate,Counting for Adjustment of Mealtime Insul...n Diabetes Association,s (ADA) medical journal,Di...
(Date:7/22/2008)...h chemotherapy and pegylated enzyme produces si...rapy alone - - Pegylated enzyme w...irstCall/ -- Halozyme Therapeutics,Inc. (Nasdaq: ...d,commercializing products targeting the extracell...ositive pre-clinical animal efficacy data,for its ...
Breaking Medicine Technology:CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 2Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 3Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 5Whole Grains Do a Heart Good 4300 1Whole Grains Do a Heart Good 4300 2Whole Grains Do a Heart Good 4300 3Saks Fifth Avenue Unveils Five Magical Holiday Gifts 4296 1Saks Fifth Avenue Unveils Five Magical Holiday Gifts 4296 2Saks Fifth Avenue Unveils Five Magical Holiday Gifts 4296 3Neptune Society Opens Tucson Arizona Office 4292 1Neptune Society Opens Tucson Arizona Office 4292 2Markel Expands Classes for Contagion Risk with OUTBREAK 28R 29 Extra Expense Coverage 4288 1Markel Expands Classes for Contagion Risk with OUTBREAK 28R 29 Extra Expense Coverage 4288 2
(Date:7/25/2008)...ON, July 25 /PRNewswire/ -- The Elekta Family of C... treatment solutions at the 2008,American Associat...g,demonstrating how the joint forces of Elekta, I... therapy planning and delivery solutions that,stre...perience for,patients, as well as enhance clinicia...
(Date:7/25/2008)...ds fluid back-up in esophagus can cause immune sys...ay News) -- The first evidence linking gastroesoph...scovered by Duke University Medical Center researc...ns was first noted in the 1970s, and since then st...rcent of asthma patients also experience GERD symp...
(Date:7/25/2008)... The Retina Group of New York will...ted macular degeneration especially designed for s...e Public Library at 116 Merritts Road, Farmingdale.... Attendance is free and refreshments will be prov...6) 939-6100. , Hicksville...
(Date:7/25/2008)... This donation will be used to fac...ve services for children , ... ( www.ivci.com ), a leading integrator of enterp...tion video conferencing, telepresence, audio visua...announced today that it has donated video conferen...
Breaking Medicine News(10 mins):Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:People With GERD More Likely to Develop Asthma 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2
...ncer, such as radiotherapy, surgery and drugs as w...edical training// vary throughout the EU, accordin... Medical Oncology (ESMO) on 3 October 2006. Access...om country to country. The survey published in Me...
...ur of daily physical exercise for their future goo...agues at Glasgow University studied 545 children a...red the children who had the recommended adult lev...s, three times a week, reported the online edition...
...al health wards have been graded as unpleasant or ...atients//. The charity called Mind revealed that ...te of repair of their ward while 28% were not sati...Mind is for patients to be treated in a therapeuti...
...erts, some cancer patients are experiencing unjust...te of the new legislation to protect their rights/...fect from the end of last year has provided effect...h severe illnesses like cancer, multiple sclerosis...
Other Medicine News:Health News:Mental Health Wards rated unpleasant 2Health News:Injustice to cancer patients at work 2
Acetate Plate Sealers 100/Box
...croseal 'B' seals provide an adhesive-based sealin...tes. The aggressive adhesive layer ensures secure ...g, and tight sealing during thermal cycling when s...he perforated end-tabs can be removed when using t...
TD silicone foam compression pad. Use with plates sealed with TDX or OptiTape.
Inquire
Medicine Products: